Aridis Pharmaceuticals, Inc. (ARDS)

Market Cap	10.66K -99.7%
Revenue (ttm)	22.36M +680.4%
Net Income	-1.14M
EPS	-0.04
Shares Out	53.32M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	10,252
Open	0.0002
Previous Close	n/a
Day's Range	0.0002 - 0.0002
52-Week Range	0.0000 - 0.0500
Beta	3,877.58
RSI	48.06
Earnings Date	n/a

About Aridis Pharmaceuticals

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 37
• Stock Exchange: OTCMKTS
• Ticker Symbol: ARDS

Financial Performance

In 2022, Aridis Pharmaceuticals's revenue was $3.09 million, an increase of 101.37% compared to the previous year's $1.54 million. Losses were -$30.37 million, -34.43% less than in 2021.